Glaxo Wellcome in the USA has selected Health Delivery Systems, a unit of McKesson Corp, to redesign, implement and administer the company's comprehensive patient assistance program (PAP) for GW's marketed pharmaceuticals.
A PAP aims to help uninsured and/or under-insured patients who cannot afford the cost of therapy, and who meet certain financial, insurance and medical criteria, to obtain the medication they need. The HDS-designed PAP will cover over 50 GW products for patients throughout the USA and its territories. Patients who qualify for this PAP will be able to get drugs from a network of over 54,000 commun-ity pharmacies in the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze